Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats

Gut

Volumn 43, Issue 3, 1998, Pages 365-374

  Stadnicki, A ^a   Sartor, R B ^b   Janardham, R ^b   Stadnicka, I ^a   Adam, A A ^c   Blais Jr , C ^c   Colman, R W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bradykinin 2 receptor; Enterocolitis; Indomethacin; Kininogen; Plasma kallikrein; Proteoglycan polysaccharide

Indexed keywords

BRADYKININ B2 RECEPTOR; INDOMETACIN; KALLIKREIN; KININOGEN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE; PROTEOGLYCAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ENTERITIS; ENTEROCOLITIS; FEMALE; GENETIC SUSCEPTIBILITY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031668914     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.3.365     Document Type: Article

References (48)

1. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995;24:475-508.
2. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
3. Sartor RB, DeLa Cadena RA, Green KD, et al. Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996;110:1467-81.
4. Schwab JH. Phlogistic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal-flora bacteria which colonize humans. Infect Immun 1993;61:4535-9.
5. Stadnicki A, DeLa Cadena RA, Sartor RB, et al. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. Dig Dis Sci 1996;41:912-20.
6. DeLa Cadena RA, Wachtfogel YT, et al. Contact activation pathway: inflammation and coagulation. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1994:219-40.
7. Schapira M, Despland E, Scott CF, et al. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982;69:1199-202.
8. Wachtfogel YT, Kucich U, James HL, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-7.
9. Zimmerli W, Huber I, Bouma BN, et al. Purified human plasma kallikrein does not stimulate but primes neutrophils for superoxide production. Thromb Haemost 1989;62: 1121-5.
10. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins, kallikrein, kininogens and kinases. Pharmacol Rev 1992;44:1-80.
11. Gaginella TS, Kachur JF. Kinins as mediators of intestinal secretion. Am J Physiol 1989;256;G1-15.
12. Stadnicki A, Sartor RB, Janardham R, et al. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J 1998;12:325-33.
13. Colman RW, Flores DN, De La Cadena RA, et al. Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental Gram-negative septicemia. Am J Pathol 1988; 130:418-26.
14. Pixley RA, DeLa Cadena RA, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-8.
15. Pixley RA, Zellis S, Bankes P, et al. Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 1995;23: 41-51.
16. Sartor RB, Bender DE, Holt LC. Susceptibility of inbred rat strains to intestinal inflammation induced by indomethacin [abstract]. Gastroenterology 1992;102:A690.
17. Schreiber GA, Tsykin A, Aldred AR, et al. The acute phase response in the rodent. Ann N Y Acad Sci 1989;557:61-86.
18. Rath HC, Herforth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
19. DeLa Cadena RA, Scott CF, Colman RW. Evaluation of a microassay for human plasma prekallikrein. J Lab Clin Med 1987;109:601-7.
20. Scott CF, Colman RW. A simple and accurate microplate assay for the determination of factor XI in plasma. J Lab Clin Med 1988;111:708-14.
21. Colman RW, Bagdasarian A, Talamo RC, et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975;56:1650-62.
22. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961;36:212-19.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
24. Hjelm H, Hjelm K, Sjoquist J. Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett 1972;28:73-6.
25. Hock J, Vogel R, Linke RP, et al. High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies. J Biol Chem 1990;265:12005-11.
26. Adam A, Damas J, Calay G, et al. Quantification of rat T-kininogen using immunological methods. Application to inflammatory processes. Biochem Pharmacol 1989;38: 1569-75.
27. Figueroa CD, Gonzalez CB, Grigoriev S, et al. Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem 1995;43: 137-48.
28. Tallarida RJ, Murray RG. Manual of pharmacologic calculations with computer programs. New York: Springer-Verlag, 1987:121-20.
29. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969;54:237-49.
30. Robert A. An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology 1975;69:1045-7.
31. Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977;22: 749-60.
32. Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992;27:721-6.
33. Banerjee AK, Peters TJ. Experimental non-steroidal antiinflammatory drug-induced enteropathy in the rat similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut 1990;31:1358-64.
34. Yamada T, Deitch E, Specian RD, et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-62.
35. Blais C Jr, Couture R, Drapeau G, et al. Endogenous kinins are involved in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum 1997;40:1327-33.
36. Schreiber G, Tsykin A, Aldred AR, et al. The acute phase response in the rodent. Ann N Y Acad Sci 1989;557:61-85.
37. Sartor RB, Holt L, Bender DE, et al. Prevention and treatment of experimental enterocolitis with a recombinant interleukin-1 receptor antagonist [abstract]. Gastroenterology 1991;100:A613.
38. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-47.
39. Whittle BJ. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981;80:94-8.
40. Redfern JS, Blair AJ, Lee E, et al. Gastrointestinal ulcer formation in rabbits immunized with prostaglandin E2. Gastroenterology 1987;93:744-52.
41. Miura S, Suematsu M, Tanaka S, et al. Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol 1991;261:G213-19.
42. Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983;301:214-21.
43. Conner EM, Brand SJ, Davis JM, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression. Inflammatory Bowel Disease 1996;2:133-47.
44. Sartor RB, Bender DE, Guenther R, et al. Absolute requirement for ubiquitous luminal bacteria in the pathogenesis of chronic intestinal inflammation [abstract]. Gastroenterology 1994;106:A747.
45. Banerjee AK. Enteropathy induced by non-steroidal antiinflammatory drugs. BMJ 1989;298:1539-40.
46. Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-9.
47. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-16.
48. Stadnicki A, Gonciarz M, Niewiarowski TJ, et al. Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis. Dig Dis Sci 1997;42: 2356-66.